ライフサイエンスコーパス: oncocytoma

1 is up-regulated in RCC and down-regulated in oncocytoma.

2 pe 2 papillary, chromophobe, TFE3, TFEB, and oncocytoma.

3 ignant renal cell carcinoma (RCC) and benign oncocytoma.

4 y be a molecular basis for the occurrence of oncocytomas.

5 rentiation between clear cell carcinomas and oncocytomas.

6 f 12 (25%) clear cell RCCs, but 0 of 4 renal oncocytomas.

7 in was detected primarily in chromophobe RCC/oncocytomas.

8 mples, including nonpapillary, papillary and oncocytomas.

9 multiple chromosomal arms in CDCs and renal oncocytomas.

10 ing diversion of tumor progression to benign oncocytomas.

11 %) sporadic renal tumors: 2 of 7 (29%) renal oncocytomas, 1 of 9 (11%) chromophobe RCCs, 4 of 11 (36%

12 x10(-3) mm(2)/s; p<0.05 and in patients with oncocytoma - 2.75+/-0.27x10(-3) mm(2)/s vs. 2.11+/-0.25x

13 The mean and peak perfusion levels of oncocytoma (373.9 mL/min/100 g +/- 99.2 and 512.3 mL/min

14 (208.0 mL/min/100 g +/- 41.1, P = .001), and oncocytoma (373.9 mL/min/100 g +/- 99.2, P < .001).

15 d MITF), chromophobe kidney cancer (5%), and oncocytoma (5%).

16 enal tumors of different cell types: 7 renal oncocytomas, 9 chromophobe renal cell carcinomas (RCCs),

17 of the renal cell carcinoma, 5 patients with oncocytoma and 5 patients with angiomyolipoma (AML).

18 the molecular classification of chRCC, renal oncocytoma and pRCC.

19 itary kidney cancer syndromes, like familial oncocytoma and the Birt-Hogg-Dube syndrome, have been id

20 can be used to differentiate solid RCCs from oncocytomas and characterize the histologic subtypes of

21 167 primary human tumors that included renal oncocytomas and non-clear cell renal cell carcinomas (nc

22 most of the tested markers in seven of eight oncocytomas and one of 69 clear cell carcinomas.

23 he five false-positive masses included three oncocytomas and two Bosniak category 3 cystic lesions.

24 in BHD(d/+) mice including oncocytic hybrid, oncocytoma, and clear cell with concomitant loss of hete

25 f 170 clear cell RCCs, 57 papillary RCCs, 49 oncocytomas, and 22 chromophobe RCCs were evaluated for

26 uding pyelonephritis, renal cysts, adenomas, oncocytomas, and normal kidney, did not express the MN/C

27 carcinomas, six chromophobe carcinomas, four oncocytomas, and one angiomyolipoma were analyzed.

28 RCCs were distinguished from chromophobe RCC/oncocytomas based on large-scale gene expression pattern

29 complex in tumors, is up-regulated in benign oncocytoma but down-regulated in RCC.

30 y chromophobe renal cell carcinoma and renal oncocytoma but not by clear cell renal cell carcinoma or

31 e further distinguished from chromophobe RCC/oncocytomas by overexpression of vimentin and class II m

32 Oncocytomas demonstrate higher perfusion levels than RCC

33 Chromophobe RCC/oncocytomas displayed similar expression profiles, inclu

34 ilies (chromophobe: amylases 1A, 1B, and 1C; oncocytoma: general transcription factors 2H2, 2B, 2C, a

35 iomyoma renal cell carcinoma, familial renal oncocytoma, hereditary nonpolyposis colon cancer, and me

36 gnificantly between clear cell carcinoma and oncocytoma in any phase (P = .2081-.6000).

37 RCCs including papillary, nonpapillary, and oncocytomas in order to determine whether allelic loss c

38 of clear cell RCCs was greater than that of oncocytomas in the corticomedullary (125 HU vs 106 HU, P

39 In renal oncocytomas, LOH of 1q occurred in approximately 30% of

40 even segments), clear cell (three segments), oncocytoma (nine segments), and papillary type 2 (two se

41 omophobe, and 10 unclassified carcinomas; 16 oncocytomas; nine angiomyolipomas).

42 ients with RCC but is nearly undetectable in oncocytoma, other tumors, and urinary tract inflammation

43 t helped to discriminate clear cell RCC from oncocytoma, papillary RCC, and chromophobe RCC with accu

44 in the discrimination of clear cell RCC from oncocytoma, papillary RCC, and chromophobe RCC.

45 ma (RCC) specimens (chromophobe, clear cell, oncocytoma, papillary type 1, and papillary type 2) usin

46 Mean enhancement of clear cell RCCs and oncocytomas peaked in the corticomedullary phase; mean e

47 d tumor fate from adenomas and carcinomas to oncocytomas-rare, predominantly benign tumors characteri

48 l chromophobe renal cell carcinoma and renal oncocytoma seem to originate from the A-type intercalate

49 e 26 benign small renal masses (including 18 oncocytomas, seven lipid-poor angiomyolipomas, and one h

50 ns; 24 (12%), chromophobe adenomas; 14 (7%), oncocytomas; six (3%), lipid-poor angiomyolipomas; and 1

51 bserved on arms 8p, 14q, 19q, and 21q in the oncocytomas studied.

52 es in clear cell, papillary, chromophobe RCC/oncocytoma, TCC and Wilms' subtypes.

53 Clear cell RCCs and oncocytomas tended to be hypervascular, chromophobe lesi

54 e chromophobe RCC, five sarcomatoid RCC, two oncocytomas, three transitional cell carcinomas (TCC) of

55 ared segments ranged from a 6.1-kb deletion (oncocytomas) to a 208.3-kb deletion (chromophobes).

56 family of neoplasms ranging from the benign oncocytoma, to the indolent papillary and chromophobe ca

57 rcinomas (RCC), one chromophobe RCC, and two oncocytomas using cDNA microarrays.

58 s versus cystic RCC, adenoma versus RCC, and oncocytoma versus granular cell RCC.

59 imaging-based diagnosis of solid RCC versus oncocytoma was 0.854.

60 The mean tumor perfusion of oncocytoma was higher than that of clear cell RCC (P < .

61 The MIN in some oncocytomas was of the RER+ (replication error) type I p

62 hree families classified with familial renal oncocytoma were identified with BHD mutations, which rep

63 ations, chromophobes, clear-cell tumors, and oncocytomas were composed exclusively of noncoding DNA.

64 All seven oncocytomas were considered to be malignant with both me

65 When the oncocytomas were excluded, specificities increased to 83

66 llecting duct carcinomas (CDCs) and 13 renal oncocytomas were studied using highly informative micros

67 were malignant, and 19 (20%)-including seven oncocytomas-were benign.

68 d to derive a cohort of 298 cases of RCC and oncocytoma with preoperative multiphasic multidetector C